Companies ›Healthcare ›109960.KQ

109960.KQ — KOSDAQ Pharmaceuticals

109960.Kq

$1 878,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-89,8 %

ROE

-1,8 %

Net margin

-56,7 %

Debt / equity

0,02

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.

Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-1,8 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 109960.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 109960.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and biologics.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

The company's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage position relative to its equity base. Despite this, the company reported negative free cash flow of -5.5 billion KRW, driven by a significant operating cash flow of 2.4 billion KRW and capital expenditures of -14.09 million KRW. The negative net cash position, after subtracting total debt, raises liquidity concerns.

Profitability metrics show a challenging performance, with a return on equity of -1.81% and a return on assets of -1.73%. These figures are below the industry median for pharmaceutical companies, which typically exhibit positive returns due to high-margin product lines and R&D investments. The company's operating loss of 8.8 billion KRW and net loss of 5.56 billion KRW further underscore its current financial strain.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation and geographic exposure increases vulnerability to market-specific risks, such as regulatory changes or demand fluctuations in a single region.

Growth trajectory appears negative, with the company reporting a net loss in the latest period. Historical revenue data is not available for trend analysis, but the current operating and net losses suggest a contraction in profitability. The outlook for the next fiscal year remains uncertain without a clear path to positive earnings.

Risk factors include a medium liquidity risk due to negative free cash flow and a net cash position that is negative after subtracting total debt. The dilution risk is currently low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's negative earnings and cash flow could lead to future dilution if it raises capital through equity issuance.

Recent events include the latest financial filing, which disclosed the company's operating and net losses. No recent earnings call transcripts or regulatory filings have been identified that provide additional insight into the company's strategic direction or operational performance.

Key takeaways

The company is operating at a net loss, with a return on equity of -1.81% and a return on assets of -1.73%.
Free cash flow is negative at -5.5 billion KRW, despite a positive operating cash flow of 2.4 billion KRW.
The company's capital structure is conservative, with a debt-to-equity ratio of 0.02.
Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
Liquidity risk is medium due to negative free cash flow and a net cash position that is negative after subtracting total debt.
Dilution risk is currently low, but the company's financial performance could lead to future equity issuance.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$1 878,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$306.59B

Net cashⓘ

-$6.24B

Current ratioⓘ

3.0

Debt / equityⓘ

0.0

ROAⓘ

-1.7%

ROEⓘ

-1.8%

Cash conversionⓘ

-44.0%

CapEx / revenueⓘ

-0.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-89,8 %Bottom quartile

Net Margin-56,7 %Bottom quartile

ROE-1,8 %Below median

Capex / Rev-0,1 %Above P75

D/E0,02Above median

Cash Conv-0,44Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

109960.KQ Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

109960.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread